SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

SimBioSys received FDA 510(k) clearance for TumorSight Risk, an AI tool that predicts 5- and 10-year breast cancer recurrence risk using MRI, pathology, and clinical data for HR-positive, HER2-negative breast cancer patients.